Clinical Trial Update: Niraparib Efficacy in Patient With Unresectable Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update shows Niraparib efficacy in a patient with unresectable malignant mesothelioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• Zejula (Niraparib)

Snippet

Sponsor: University Hospital Southampton NHS Foundation Trust | Conditions: Mesothelioma, Malignant | Phase 2 | Status: COMPLETED